-
RIVM. Registratie infectieziekten. Meldingen wet publieke gezondheid. Infectiebulletin. 2018;29:12, en 2019;30:2.
-
Sijbom M, Numans ME, Perquin MJ, et al. NHG-Standaard Virushepatitis en andere leveraandoeningen. Huisarts Wet. 2016;50:666-81.
-
Koopsen J, van Steenbergen JE, Richardus JH, et al. Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population. Epidemiol Infect. 2019;147:e147.
-
Vriend HJ, van de Laar TJ, Urbanus AT, et al. Hepatitis C virus seroprevalence in the Netherlands. Eur J Public Health. 2012;22:819-21.
-
-
Hofman R, Nusselder WJ, Veldhuijzen IK, et al. Sterfte aan chronische hepatitis B en C virusinfectie in Nederland. Ned Tijdschr Geneeskd. 2016:160:D511.
-
Hoofnagle JH. Hepatitis C: The Clinical Spectrum of Disease – Hepatology. 1997;26:Suppl.1,15S-20S.
-
Peng CY, Chien RN, Liaw YF, et al. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442-50.
-
Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Eng J Med. 2015: 373:2618-28.
-
Marschall T, Kretzschmar M, Mangen MJ, et al. High impact of migration on the prevalence of chronic hepatitis B in the Netherlands. Eur J Gastroenterol Hepatol. 2008;20:1214-25.
-
Vriend HJ, van Veen MG, Prins M, et al. Hepatitis C virus prevalence in The Netherlands: migrants account for most infections. Epidemiol Infect. 2013;141:1310-17.
-
Arnold DT, Bentham LM, Jacob RP, et al. Should patients with abnormal liver function tests in primary care be tested for chronic viral hepatitis: cost minimisation analysis based on a comprehensively tested cohort. BMC Fam Pract. 2011;12:9.
-
Helsper C, van Essen G, Frijling BD, et al. Follow-up of mild alanine aminotransferase elevation identifies hidden hepatitis C in primary care. Br J Gen Pract. 2012;62:e212-6.
-
Mohamoud YA, Mumtaz GR, Riome S, et al. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis BMC Infectious Diseases 2013;13:288.
-
Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of Hepatitis C Virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2013;60:691-698.
-
Wolffram I, Petroff D, Bätz O, et al. Prevalence of elevated ALT levels, HBsAg and anti-HCV in primary care setting. J Hepatol. 2015:62:1256-64.
-
Tsai MC, Lee CM, Chiu KW, et al. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice. J Antimicrob Chemother. 2012;67:696-9.
-
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Eng J Med. 2014;370:211.
-
-
Helsper CW, van Essen GA, Bonten MJ, et al. A support programme for primary care leads to substantial improvements in the effectiveness of a public hepatitis C campaign. Fam Pract. 2010;27:328-32.
-
Helsper CW, Borkent-Raven BA, de Wit NJ, et al. Cost-effectiveness of targeted screening for hepatitis C in the Netherlands. Epidemiol Infect. 2012;140:58-69.
-
Stoffels M, Undral, ingezonden artikel Medisch Contact, 18 mei 2007;62-20.
Account
1
